Clinical trial AMG510
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2018-001400-11 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03600883 |
| Inclusion criteria | Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation |
| Last update |